JACC: Basic to Translational Science (Feb 2018)

Subcutaneous Furosemide in Heart Failure

  • Domenic A. Sica, MD,
  • Pieter Muntendam, MD,
  • Rene L. Myers, PhD,
  • Jozine M. ter Maaten, MD, PhD,
  • Mark E. Sale, MD,
  • Rudolf A. de Boer, MD, PhD,
  • Bertram Pitt, MD

DOI
https://doi.org/10.1016/j.jacbts.2017.10.001
Journal volume & issue
Vol. 3, no. 1
pp. 25 – 34

Abstract

Read online

Parenteral diuretics form the cornerstone of decongestion in heart failure. However, parenteral therapy routinely requires emergency room or inpatient care. A novel buffered furosemide formulation with neutral pH was developed to offer “hospital-strength” diuresis for outpatient use, including self-administration at home. Subcutaneous infusion using a biphasic delivery profile resulted in complete bioavailability (99.65%) and equivalent diuresis when compared with intravenous administration. Subcutaneous administration of buffered furosemide was well tolerated with no evidence of any drug-induced skin reactions. Subcutaneous infusion of buffered furosemide in the outpatient setting or home may help to reduce the burden of heart failure.

Keywords